We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
News

SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes

SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
News

SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis’ lead drug candidate VRS-859, a novel GLP-1 analog for monthly dosing to treat type 2 diabetes   Under the agreement, SynCo will further develop the Versartis existing production process for VRS-859 and optimize the manufacturing process to increase yields for the forthcoming cGMP production. 
 
VRS-859 is a recombinant fusion protein containing exenatide and XTEN™, a novel hydrophilic amino acid sequence that prolongs the half life of proteins and peptides.  New therapeutic compounds using the XTEN technology are expected to provide enhanced stability and less frequent dosing requirements with potentially fewer patient side effects.
 
“Versartis selected SynCo because of its extensive pharmaceutical manufacturing experience and its ability to deliver bulk and final product for clinical trials and ultimately, for commercialization,” said Jeffrey L. Cleland, Ph.D., Founder and Chief Executive Officer of Versartis.  “We expect SynCo to ensure our goal of initiating Phase 1 clinical trials for VRS-859 in the first half of 2010.  SynCo will also become our preferred manufacturing partner for future Versartis products based on the XTEN technology, which have similar production processes.”
 
Pierre Warffemius, SynCo Bio Partners Chief Executive Officer commented, “We are delighted that SynCo has been chosen to develop and manufacture Versartis’ lead compound VRS-859.  As Versartis looks to advance its novel product portfolio through clinical trials, we look forward to a long and successful collaboration with this exciting new company.”
Advertisement